Clinical Effect of Memantine Hydrochloride Combined with Carbidopa-levodopa Sustained Release Tablet on Motor Symptoms in Patients with Parkinson's Disease

Jiayi  Gu; Xiujing  Fu; Qiaowen  Tong; Yiting  Ni; Hua Ye

doi:10.62767/

Authors

Jiayi Gu Department of Neurology, Wenzhou People's Hospital, 325000 Wenzhou, Zhejiang, China Author
Xiujing Fu Department of Neurology, Wenzhou People's Hospital, 325000 Wenzhou, Zhejiang, China Author
Qiaowen Tong Department of Neurology, Wenzhou People's Hospital, 325000 Wenzhou, Zhejiang, China Author
Yiting Ni Department of Neurology, Wenzhou People's Hospital, 325000 Wenzhou, Zhejiang, China Author
Hua Ye Department of Neurology, Wenzhou People's Hospital, 325000 Wenzhou, Zhejiang, China Author

DOI:

https://doi.org/10.62767/

Keywords:

memantine hydrochloride, carbidopa-levodopa sustained release tablet, parkinson’s disease, motor symptoms

Abstract

Background: To investigate the clinical effect of memantine hydrochloride combined with carbidopa-levodopa sustained release tablet on motor symptoms in patients with Parkinson’s disease. Methods: 45 patients with Parkinson’s disease receiving treatment of memantine hydrochloride combined with carbidopa-levodopa sustained release tablet in our hospital from September 25^th, 2025 to December 25^th, 2025 were included as the study group, and 45 Parkinson’s disease patients treated with carbidopa-levodopa sustained release tablet were included as the control group during the same period. The clinical efficacy, adverse reactions, and changes of motor symptoms and serum indexes before and after treatment were compared between the two groups. Results: The total effective rate of clinical efficacy in the study group was higher than that in the control group (P < 0.05). After treatment, UPDRS-Ⅲ scores and levels of IL-1β, IL-17, Hcy, TNF-α and MDA were decreased in both groups, and were lower in the study group than the control group (P < 0.05). The levels of SOD and GSH-Px in both groups were increased, and were higher in the study group than the control group (P < 0.05). There was no significant difference in gastrointestinal reaction, lethargy, dizziness, headache and postural hypotension between the two groups (P > 0.05). Conclusion: Memantine hydrochloride combined with carbidopa-levodopa sustained release tablets has good clinical effects in the treatment of Parkinson’s disease through reducing motor symptoms, inhibiting inflammatory response, improving oxidative stress, etc., with good safety.

References

Huang Y, Chen X. Efficacy and potential mechanisms of Bushen Huoxue Shugan Decoction combined with Western medicine on Parkinson’s disease. Hebei Journal of Traditional Chinese Medicine 2024; 46(4): 574-577+582.

Magrinelli F, Picelli A, Tocco P, et al. Pathophysiology of Motor Dysfunction in Parkinson’s Disease as the Rationale for Drug Treatment and Rehabilitation. Parkinson’s Disease 2016; 6(6): 9832839.

Kalia LV, Lang AE. Parkinson’s disease. The Lancet 2015; 386(9996): 896-912.

Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nature Reviews Disease Primers 2017, 23(3): 17013.

Morgan J, Sethi KD. Levodopa and the progression of Parkinson’s disease. Current Neurology and Neuroscience Reports 2005; 5(4): 261-2.

Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nature Reviews Neuroscience 2017, 18(7): 435-50.

Aarsland D, Påhlhagen S, Ballard CG, et al. Depression in Parkinson disease—epidemiology, mechanisms and management. Nature Reviews Neurology 2012, 8(1): 35-47.

Van Kessel SP, Frye AK, El-Gendy AO, et al. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of parkinson’s disease. Nature Communications 2019, 10(1): 310-313.

Zhao JW, Guo YK. Effect of Bushen Huoxue Prescription Combined with Carbidopa and Levodopa Sustained-Release Tablets on Levels of Adiponectin,TNF-α and IL-6 in Serum and Cognitive Function of Patients with Parkinson Disease. Journal of New Chinese Medicine 2022, 54(8): 72-76.

Tang BC, Wang YT, Ren J. Basic information about memantine and its treatment of Alzheimer’s disease and other clinical applications. Ibrain 2023, 9(3): 340-348.

Huang Q, Sun QJ, Guan JZ, et al. Effect of memantine hydrochloride combined with piribedil in the treatment of Parkinson’s disease and its influence on cognitive function and motor function. BMC Neurology 2022, 13(5): 175.

Li J, Jin M, Wang L, et al. MDS clinical diagnostic criteria for Parkinson’s disease in China. Journal of Neurology 2017, 264(3): 476-481.

Qu Y, Li XH, Sun YN, et al. Evaluation for Parkinson’s Disease with Chinese Version of MDS-UPDRS and Original UPDRS. Chinese Journal of Rehabilitation Theory and Practice 2019, 25(8): 936-939.

Han L, Su XZ, Zhang ZY, et al. Effect of panlong needling at Jiaji (EX-B 2) on motor dysfunction in patients with Parkinson’s disease of liver and kidney deficiency: a randomized controlled trial. Zhongguo Zhen Jiu 2022, 42(5): 493-7.

Moustafa AA, Chakravarthy S, Phillips JR, et al. Motor symptoms in Parkinson's disease: A unified framework. Neuroscience & Biobehavioral Reviews 2016, 68(9): 727-740.

Klamroth S, Steib S, Devan S, et al. Effects of exercise therapy on postural instability in parkinson disease: a meta-analysis. Journal of Neurologic Physical Therapy 2016, 40(1): 3-14.

Wang JL, Wu LL. Clinical Efficacy of Memantine Hydrochloride in the Treatment of Parkinson’s Disease. Journal of Aerospace Medicine 2023, 34(3): 269-271.

Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. The Lancet Neurology 2010, 9(10): 969-77.

Jiang MF, Niu GM, Shi F, et al. The application of 1H MRS in Parkinson’s disease. Chinese Journal of Difficult and Complicated Cases 2017, 16(10): 1010-1013.

Park SH, Choe JY, Kim SK, et al. Routine assessment of patient index data (ＲAPID3) and bath ankylosing spondylitis disease activity index (BASDAI) scores yield similar information in 85 korean patients with ankylosing spondylitis seen in usual clinical care. Journal of Clinical Rheumatology 2015, 21(6): 300-304.

Zang CX, Bao XQ, Sun H, et al. The role of neuroinflammation-related regulatory targets in the treatment for Parkinson’s disease. Acta Pharmaceutica Sinica 2016, 17(5): 677-683.

Hickman S, Izzy S, Sen P, et al. Microglia in neurodegeneration. Nature Neuroscience 2018, 21(10): 1359-1369.

Di Rita A, Strappazzon F. Mitophagy could fight Parkinson’s disease through antioxidant action. Reviews in the Neurosciences 2019, 30(7): 729-742.

Pizzino G, Irrera N, Cucinotta M, et al. Oxidative Stress: Harms and Benefits for Human Health. Oxidative Medicine and Cellular Longevity 2017: 8416763.

Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson’s disease. Journal of Parkinson’s Disease 2013; 3(4): 461-91.

Qiao O, Zhang XY, Zhang Y, et al. Cerebralcare Granule® enhances memantine hydrochloride efficacy in APP/PS1 mice by ameliorating amyloid pathology and cognitive functions. Chinese Medicine 2021, 28(6): 47.

Choi H, Hwang S, Cho H, et al. Memantine modulates neuroinflammation and motor coordination in a Parkinson’s disease model. Brain Research 2025, 1869: 150034.

Tang BC, Wang YT, Ren J. Basic information about memantine and its treatment of Alzheimer’s disease and other clinical applications. iBrain 2023, 9(3): 340-348.